Compare AbCellera Biologics Inc (ABCL) vs Msci Inc (MSCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Msci Inc — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Msci Inc trades at $603.69 (market cap $44.27B). The key difference: Msci Inc is far larger — about 18.8× AbCellera Biologics Inc's market cap, and Msci Inc pays a 1.35% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MSCI | |
|---|---|---|
Market Cap | $2.35B | $44.27B |
Sector | Health | Financials |
52-Week High | $8.12 | $643.83 |
52-Week Low | $2.78 | $511.84 |
Enterprise Value | $1.99B | $50.43B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MSCI trades at $608.09, up 0.83% with a bullish technical outlook and strong fundamental performance. The company delivered three consecutive quarterly earnings beats, maintains exceptional profit margins above 40%, and shows consistent revenue growth. Recent strategic acquisitions and AI integration initiatives position MSCI for continued market leadership in financial analytics and index services.
With 69% analyst buy ratings and a $700.50 consensus price target representing 15% upside, MSCI offers growth potential despite premium valuations. Key risks include high debt levels and market classification decisions impacting revenue streams. The stock's current technical setup near pivot point $606 suggests potential for continued upward momentum if earnings momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
